Healthcare company Lyndra Therapeutics reported on Tuesday the receipt of USD13m grant from the Bill & Melinda Gates Foundation for the planned development of an oral contraceptive that would last for multiple weeks.
The company added that the grant is part of the Bill & Melinda Gates Family Planning programme, which is working to bring access to high-quality contraceptive information, services and supplies to women in low- and middle-income countries as well as to address lack of family planning options globally.
Under the Bill & Melinda Gates Foundation funds, the company is designing and building a new once-monthly oral combination therapy that delivers a continuous dose of estrogen and progestin, the same drugs used in daily combined oral contraceptives, in collaboration with Routes2Results, a health research organization .
In addition, the company received the Bill & Melinda Gates Foundation grant for the development of a long-acting malaria drug, Phase II clinical trials as well as for expansion of its Phase I pipeline and manufacturing scale-up.
Lilly declares Q2 2025 dividend
Bruker acquires majority stake in RECIPE to expand clinical mass spectrometry diagnostics
Emmaus Life Sciences reports drop in revenues, increased loss in 2024
L'Oréal and WHO Foundation partner to expand global skin health access